Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023
Biosimilar monoclonal antibodies - this new study shows you potential sales
What does the future hold for biosimilar therapeutic antibodies? Visiongain's new report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends and opportunities.
In that study you get revenue forecasts at overall world market, submarket, product, and national level. See what's happening for those technologies, finding how you can gain.
Read on, then, to explore biosimilar monoclonal antibodies (mAbs) and see what their future market could be worth.
Forecasts to 2023 and other analyses show you commercial potentials
Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 69 tables, 52 charts, and two research interviews.
Is finding data for biosimilar mAbs a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.
There you investigate follow-on protein technology for antibodies. You hear what's happening and see where the money lies. Finding that data just got easier.
The following sections, then, show what you get in our research and analysis.
Prospects for the world market and submarkets for those follow-on biologics
Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of seven biosimilar mAb submarkets:
Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential and find ways for your business to develop.
You also find revenue predictions for products using follow-on antibody technology.
Forecasts for 13 agents - assess potential of existing and expected products
How will products perform to 2023 at world level? Our report forecasts individual revenues of 13 biosimilar antibodies, launched or in development, including these:
Our investigation also divides its overall world forecast into geographical regions.
National markets - what outlooks for sales?
Developments worldwide expand the biosimilar mAbs market. Hear about the best revenue prospects.
In developed and developing countries, many opportunities for producers of those biological drugs will occur from 2013 to 2023. See where and how.
Our analyses show you individual revenue forecasts to 2023 for 12 national markets:
Issues affecting biosimilar antibody manufacturing and selling
Our report also shows you issues and events affecting that industry and market from 2013, including these:
Biosimilar antibody-based therapies - what's the 2018 market value?
What happens next? From this decade onwards, follow-on treatments hold great potential for investment and revenues. Our study predicts the world market for biosimilar mAbs will reach $3,229m in 2018, with high growth from 2013 to 2023.
In 2012, monoclonal antibodies formed five of the top ten medicines worldwide by revenue. For those therapies, high potential for biosimilar competition exists. Our analysis predicts those competitors of the leading mAb drugs will be on sale by 2018.
Prospects for mAb biosimilars are strong, then, and from 2013 there will arise many opportunities. Our analysis shows you the possibilities, helping you stay ahead.
Nine ways Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023 helps you
To sum up, our report gives you the following knowledge:
That work gives independent analysis. You receive business intelligence found only in our new report, discovering where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.
Biosimilar mAbs - assess their potentials now, seeing what you can gain
Our study shows you data, trends, opportunities, and sales predictions for biosimilar mAbs. Avoid missing out - please order our new report now.
What does the future hold for biosimilar therapeutic antibodies? Visiongain's new report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends and opportunities.
In that study you get revenue forecasts at overall world market, submarket, product, and national level. See what's happening for those technologies, finding how you can gain.
Read on, then, to explore biosimilar monoclonal antibodies (mAbs) and see what their future market could be worth.
Forecasts to 2023 and other analyses show you commercial potentials
Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 69 tables, 52 charts, and two research interviews.
Is finding data for biosimilar mAbs a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.
There you investigate follow-on protein technology for antibodies. You hear what's happening and see where the money lies. Finding that data just got easier.
The following sections, then, show what you get in our research and analysis.
Prospects for the world market and submarkets for those follow-on biologics
Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of seven biosimilar mAb submarkets:
- Infliximab
- Rituximab
- Adalimumab
- Trastuzumab
- Bevacizumab
- Abciximab
- Other molecules (grouped analysis).
Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential and find ways for your business to develop.
You also find revenue predictions for products using follow-on antibody technology.
Forecasts for 13 agents - assess potential of existing and expected products
How will products perform to 2023 at world level? Our report forecasts individual revenues of 13 biosimilar antibodies, launched or in development, including these:
- Celltrion's Remsima
- Dr. Reddy's Reditux
- Epirus Biopharmaceuticals' BOW-015
- Boehringer Ingelheim's BI695500 and BI695501
- Fujifilm Kyowa Kirin Biologics' forms of adalimumab and bevacizumab
- Biocon's Bmab200
- BIOCAD's BCD-022
- Isu Abxis's Clotinab
- Reliance Life Sciences' R-TPR-019.
Our investigation also divides its overall world forecast into geographical regions.
National markets - what outlooks for sales?
Developments worldwide expand the biosimilar mAbs market. Hear about the best revenue prospects.
In developed and developing countries, many opportunities for producers of those biological drugs will occur from 2013 to 2023. See where and how.
Our analyses show you individual revenue forecasts to 2023 for 12 national markets:
- US and Japan
- Germany, France, UK, Italy, and Spain (EU5)
- China, India, Brazil, Russia (BRIC), and South Korea.
Issues affecting biosimilar antibody manufacturing and selling
Our report also shows you issues and events affecting that industry and market from 2013, including these:
- Demand for biosimilars - rising production needs
- Research and development (R&D) for those protein-based medicines
- FDA biosimilar guidelines and state regulation of biosimilar substitution
- Legal challenges for those substitute drugs
- Biobetters as a threat to biosimilars
- EMA regulations, and those of other regions
- Collaboration in follow-on mAb development
- Big pharma and the biosimilar mAbs market.
Biosimilar antibody-based therapies - what's the 2018 market value?
What happens next? From this decade onwards, follow-on treatments hold great potential for investment and revenues. Our study predicts the world market for biosimilar mAbs will reach $3,229m in 2018, with high growth from 2013 to 2023.
In 2012, monoclonal antibodies formed five of the top ten medicines worldwide by revenue. For those therapies, high potential for biosimilar competition exists. Our analysis predicts those competitors of the leading mAb drugs will be on sale by 2018.
Prospects for mAb biosimilars are strong, then, and from 2013 there will arise many opportunities. Our analysis shows you the possibilities, helping you stay ahead.
Nine ways Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023 helps you
To sum up, our report gives you the following knowledge:
- Revenue to 2023 of the world market for biosimilar mAbs - discover that industry's overall sales potential
- Revenues to 2023 for 7 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and sales
- Revenues to 2023 for 13 follow-on protein products - find sales outlooks for top brands, and expected agents, seeing how they can compete and succeed
- Forecasts to 2023 for 12 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth
- Assessments of top companies - hear about participants' activities, capabilities, results, and outlooks
- Review of R&D - explore progress in research and development, finding technological and commercial possibilities
- Interviews with authorities in the industry - discover debates and opinions to help you stay ahead
- Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages
- Prospects for established competitors and firms seeking to enter that sector - explore needs, practices, and outlooks for future success.
That work gives independent analysis. You receive business intelligence found only in our new report, discovering where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.
Biosimilar mAbs - assess their potentials now, seeing what you can gain
Our study shows you data, trends, opportunities, and sales predictions for biosimilar mAbs. Avoid missing out - please order our new report now.
1. EXECUTIVE SUMMARY
1.1 What This Report Covers
1.2 Biosimilar MAbs: World Market Overview 2013-2023
1.3 Chapter Outlines
1.4 Research and Analysis Methods
2. INTRODUCTION TO BIOSIMILAR MONOCLONAL ANTIBODIES
2.1 Natural Antibodies: Key to the Immune System
2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)
2.3 Humanising the MAb
2.4 Biologics and Biosimilars
2.5 Why are Biosimilars in Demand?
2.6 Considerations for the Development of Biosimilars
2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
2.6.2 How Big a Concern Is Immunogenicity?
2.7 Biosimilar Monoclonal Antibodies Already on the Market
3. WORLD MARKET PROSPECTS FOR BIOSIMILAR MONOCLONAL ANTIBODIES, 2013-2023
3.1 The World Market for Biosimilar Monoclonal Antibodies in 2012: 3 Biosimilar MAbs on the Market
3.2 The World Market for Biosimilar MAbs: An Overarching Revenue Forecast, 2013-2023
3.3 The World Market for Biosimilar MAbs by Compound: Revenue and Market Share Predictions, 2018 and 2023
3.4 The World Market for Biosimilar MAbs by Compound: Grouped Revenue Forecast, 2013-2023
3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
3.4.2 Biosimilar Infliximab: High Growth Expected in 2013
3.4.2.1 Biosimilar Infliximab: Revenue Forecast, 2013-2023
3.4.3 Biosimilar Rituximab: With So Many Compounds Under Development, Will Growth Be Driven or Restrained?
3.4.3.1 Biosimilar Rituximab: Revenue Forecast, 2013-2023
3.4.4 Biosimilar Abciximab: Low Market Incentive Means Few Compounds Are in Development
3.4.4.1 Biosimilar Abciximab: Revenue Forecast, 2013-2023
3.4.5 Biosimilar Trastuzumab: The 4th Biosimilar MAb to Enter the Market
3.4.5.1 Biosimilar Trastuzumab: Revenue Forecast, 2013-2023
3.4.6 Biosimilar Adalimumab: Great Incentive to Develop Biosimilar Versions of the Leading Drug of 2012
3.4.6.1 Biosimilar Adalimumab: Revenue Forecast, 2013-2023
3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Market Restrict Revenue Generation?
3.4.7.1 Biosimilar Bevacizumab: Revenue Forecast, 2013-2023
3.5 Large Market Potential to Drive Growth to 2023
3.6 What Will Restrain the Growth of the Biosimilar MAbs Market Between 2013 and 2023?
4. PROMISING BIOSIMILAR MAB PRODUCTS AND THEIR PREDICTED FUTURE SUCCESS, 2013-2023
4.1 Biosimilar Versions on the Market: Remsima Dominates in 2012
4.1.1 Celltrion's Remsima (infliximab): The First Official Biosimilar Monoclonal Antibody
4.1.2 Dr. Reddy's Reditux (rituximab): Are US and EU Approval Expected?
4.1.3 Probiomed's Kikuzubam (rituximab): On the Market in South America
4.1.4 Instas Pharmaceuticals' Mabtas (rituximab)
4.1.5 Isu Abxis' Clotinab (abciximab): The First Biosimilar Monoclonal Antibody?
4.2 Biosimilar Versions on the Market and Promising Compounds in the Pipeline: Market Forecast, 2013-2023
4.2.1 Celltrion's Remsima (infliximab): Revenue Forecast, 2013-2023
4.2.2 Epirus Biopharmaceuticals' BOW-015 (infliximab): Revenue Forecast, 2013-2023
4.2.3 Dr. Reddy's Reditux (rituximab): Revenue Forecast, 2013-2023
4.2.4 Boehringer Ingelheim's BI695500 (rituximab): Revenue Forecast, 2013-2023
4.2.5 Celltrion's CT-P10 (rituximab): Revenue Forecast, 2013-2023
4.2.6 Boehringer Ingelheim's BI695501 (adalimumab): Revenue Forecast, 2013-2023
4.2.7 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue Forecast, 2013-2023
4.2.8 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast, 2013-2023
4.2.9 Celltrion's CT-P06 (trastuzumab): Revenue Forecast, 2013-2023
4.2.10 Biocon's Bmab200 (trastuzumab): Revenue Forecast, 2013-2023
4.2.11 BIOCAD's BCD-022 (trastuzumab): Revenue Forecast, 2013-2023
4.2.12 Isu Abxis' Clotinab (abciximab): Revenue Forecast, 2013-2023
4.2.13 Reliance Life Sciences' R-TPR-019 (abciximab): Revenue Forecast, 2013-2023
5. LEADING NATIONAL MARKETS FOR BIOSIMILAR MONOCLONAL ANTIBODIES, 2013-2023
5.1 What Were the Leading National Markets for Biosimilar Monoclonal Antibody Development in 2012?
5.2 What Were the Leading National Markets for Sales of Biosimilar Monoclonal Antibodies in 2012?
5.3 Which Markets Will Grow Fastest to 2023?
5.4 Market Shares of the Leading National Markets: All Set to Change, 2013-2023
5.5 The Outlook for Biosimilar MAbs in the US, 2013-2023
5.5.1 When Are the Final FDA Biosimilar Guidelines Expected?
5.5.2 Legal Challenges for Biosimilars in the US
5.5.3 State Regulation of Biosimilar Substitution
5.5.4 The US Biosimilar MAb Market: Revenue Forecast, 2013-2023
5.6 The Outlook for Monoclonal Antibody Biosimilars in the EU, 2013-2023
5.6.1 The EU Led the World in Biosimilar Regulation
5.6.2 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar MAbs
5.6.3 EMA Simplifies Biosimilar Development in the EU
5.6.4 Biosimilar MAbs: EU Launch in 2014?
5.6.5 Germany: Set to Become the Largest National Market for Biosimilar MAbs in the EU
5.6.6 France: Will the Uptake of Biosimilar MAbs Be Restricted?
5.6.7 UK: Drug Uptake Will Be High
5.6.8 Italy: Healthcare Spending Cuts Will Drive Growth
5.6.9 Spain: High Biosimilar MAb Discounts Expected
5.7 The Outlook for Monoclonal Antibody Biosimilars in China, 2013-2023
5.7.1 China to Release Formal Biosimilar Development Guidelines
5.7.2 China: Becoming the World's Leading Market for Biosimilar MAbs
5.8 The Outlook for Monoclonal Antibody Biosimilars in India, 2013-2023
5.8.1 India Releases New Biosimilar Development Guidelines
5.8.2 Indian Biosimilars Submarket Forecast 2013-2023
5.9 The Outlook for Monoclonal Antibody Biosimilars in Japan 2013-2023
5.9.1 Regulatory Processes for Biosimilars in Japan
5.9.2 Regulations for Naming Biosimilars
5.9.3 Biosimilar MAbs Will Be Launched in Japan in 2016
5.9.4 Japanese Biosimilar Submarket Forecast 2013-2023
5.10 South Korea: The World's leading Nation for Biosimilar MAbs
5.10.1 KFDA Introduced Biosimilar Guidelines in 2009
5.10.2 There Has Been Significant Investment in Biosimilars in South Korea
5.10.3 The Outlook for the South Korean Biosimilar MAb Market, 2013-2023
5.11 Brazil: The Third Leading Nation in the 2012 Biosimilar MAb Market, But What Will The Future Hold?
5.11.1 ANVISA's Biosimilar Regulations Are Similar to the EMA's
5.11.2 The Outlook for Monoclonal Antibody Biosimilars in Brazil, 2013-2023
5.12 The Outlook for Monoclonal Antibody Biosimilars in Russia, 2013-2023
5.12.1 No Specific Biosimilar Legislation Exists in Russia 2013
5.12.2 Russian Government Investing in Development of Biosimilars
5.12.3 Russian Biosimilar MAb Revenue Forecast 2013-2023
6. LEADING COMPANIES FOR BIOSIMILAR MABS, 2013
6.1 Prominent Companies in the Biosimilar Monoclonal Antibodies Industry, 2013
6.2 Collaboration in Biosimilar MAb Development
6.3 BioXpress: 16 Compounds in the R&D Pipeline
6.4 Celltrion: One Compound on the Market and Two in Phase III of Development, and Others Wait In The Wings
6.5 Harvest Moon: 6 Compounds Under Development
6.6 Gene Techno Science: 6 Compounds Under Development
6.7 Mabion: Poland's Leading Biosimilar MAb Developer
6.8 India's Biocon: A Quiet Competitor
6.9 Pfizer: Big Pharma Is Entering the Biosimilar MAb Market
6.10 BIOCAD
6.11 Big Pharma and the Biosimilar MAbs Market
7. QUALITATIVE ANALYSIS OF THE BIOSIMILAR MABS MARKET, 2013-2023
7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibody Market, 2013
7.1.1 Worldwide Demand for More Affordable Therapies Underpins the Market
7.1.2 The Complexity of the Molecules Engenders a Myriad of Market Weaknesses
7.2 Opportunities and Threats Facing the Biosimilar Monoclonal Antibody Market, 2013-2023
7.2.1 A Well-Stocked Pipeline in the Face of Approaching Patent Expiries: Opportunities for Market Expansion
7.2.2 Competition and Lack of Confidence: Threats to Market Penetration?
7.2.2.1 Biobetters as a Threat to Biosimilars
7.3 Social, Technological, Economic and Political Factors Influencing the Biosimilar Monoclonal Antibodies Market (STEP Analysis) 2013-2023
7.3.1 Social Factors: Driving or Restraining the Market?
7.3.2 Advances in Technology: Producing Biosimilar MAbs Cheaply and Easily
7.3.3 Economic Pressures are Driving the Demand for Biosimilar MAbs
7.3.4 Political Issues: Stringent Regulations are Hurdles to Market Entry
8. RESEARCH INTERVIEWS
8.1 Interview with Dr Xing Wang, President of Array Bridge
8.1.1 On Challenges Surrounding the Development of Biosimilar MAbs
8.1.2 On the Services Offered by Array Bridge
8.1.3 On the Demand for Biosimilar MAbs
8.1.4 On Factors Determining the Success of Biosimilar MAbs
8.1.5 On Regulatory Approval of Biosimilar MAbs: The US vs. the EU
8.2 Interview With Dr Terence Ryan, SVP, iBio
8.2.1 iBio and its Biosimilar Pipeline, 2013
8.2.2 The iBioLaunch Platform
8.2.3 Differences Between Developing Biosimilar and Biologics
8.2.4 Product Differentiation in the Biosimilar Market
8.2.5 Biosimilars and Immunogenicity
8.2.6 Challenges in Developing Biosimilars for the US Market
9. CONCLUSIONS
9.1 Biosimilar Monoclonal Antibodies: World Market, 2013-2023
9.2 The Future of Promising Pipeline Compounds
9.3 Leading National Markets for Biosimilar Monoclonal Antibodies, 2013-2023
9.4 Leading Companies in the Industry
9.5 Trends in the Industry and Market
9.5.1 Economic Pressures Stimulate Demand for MAbs
9.5.2 Patent Expiries of Several Blockbuster MAbs Are Approaching, Creating Opportunities for Biosimilars
9.5.3 Complexity of the Molecules Make Production Challenging
9.5.4 Doctor and Patient Doubt Regarding Interchangeability Will Restrict Uptake
9.5.5 Do Biobetters Pose a Threat?
1.1 What This Report Covers
1.2 Biosimilar MAbs: World Market Overview 2013-2023
1.3 Chapter Outlines
1.4 Research and Analysis Methods
2. INTRODUCTION TO BIOSIMILAR MONOCLONAL ANTIBODIES
2.1 Natural Antibodies: Key to the Immune System
2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)
2.3 Humanising the MAb
2.4 Biologics and Biosimilars
2.5 Why are Biosimilars in Demand?
2.6 Considerations for the Development of Biosimilars
2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
2.6.2 How Big a Concern Is Immunogenicity?
2.7 Biosimilar Monoclonal Antibodies Already on the Market
3. WORLD MARKET PROSPECTS FOR BIOSIMILAR MONOCLONAL ANTIBODIES, 2013-2023
3.1 The World Market for Biosimilar Monoclonal Antibodies in 2012: 3 Biosimilar MAbs on the Market
3.2 The World Market for Biosimilar MAbs: An Overarching Revenue Forecast, 2013-2023
3.3 The World Market for Biosimilar MAbs by Compound: Revenue and Market Share Predictions, 2018 and 2023
3.4 The World Market for Biosimilar MAbs by Compound: Grouped Revenue Forecast, 2013-2023
3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
3.4.2 Biosimilar Infliximab: High Growth Expected in 2013
3.4.2.1 Biosimilar Infliximab: Revenue Forecast, 2013-2023
3.4.3 Biosimilar Rituximab: With So Many Compounds Under Development, Will Growth Be Driven or Restrained?
3.4.3.1 Biosimilar Rituximab: Revenue Forecast, 2013-2023
3.4.4 Biosimilar Abciximab: Low Market Incentive Means Few Compounds Are in Development
3.4.4.1 Biosimilar Abciximab: Revenue Forecast, 2013-2023
3.4.5 Biosimilar Trastuzumab: The 4th Biosimilar MAb to Enter the Market
3.4.5.1 Biosimilar Trastuzumab: Revenue Forecast, 2013-2023
3.4.6 Biosimilar Adalimumab: Great Incentive to Develop Biosimilar Versions of the Leading Drug of 2012
3.4.6.1 Biosimilar Adalimumab: Revenue Forecast, 2013-2023
3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Market Restrict Revenue Generation?
3.4.7.1 Biosimilar Bevacizumab: Revenue Forecast, 2013-2023
3.5 Large Market Potential to Drive Growth to 2023
3.6 What Will Restrain the Growth of the Biosimilar MAbs Market Between 2013 and 2023?
4. PROMISING BIOSIMILAR MAB PRODUCTS AND THEIR PREDICTED FUTURE SUCCESS, 2013-2023
4.1 Biosimilar Versions on the Market: Remsima Dominates in 2012
4.1.1 Celltrion's Remsima (infliximab): The First Official Biosimilar Monoclonal Antibody
4.1.2 Dr. Reddy's Reditux (rituximab): Are US and EU Approval Expected?
4.1.3 Probiomed's Kikuzubam (rituximab): On the Market in South America
4.1.4 Instas Pharmaceuticals' Mabtas (rituximab)
4.1.5 Isu Abxis' Clotinab (abciximab): The First Biosimilar Monoclonal Antibody?
4.2 Biosimilar Versions on the Market and Promising Compounds in the Pipeline: Market Forecast, 2013-2023
4.2.1 Celltrion's Remsima (infliximab): Revenue Forecast, 2013-2023
4.2.2 Epirus Biopharmaceuticals' BOW-015 (infliximab): Revenue Forecast, 2013-2023
4.2.3 Dr. Reddy's Reditux (rituximab): Revenue Forecast, 2013-2023
4.2.4 Boehringer Ingelheim's BI695500 (rituximab): Revenue Forecast, 2013-2023
4.2.5 Celltrion's CT-P10 (rituximab): Revenue Forecast, 2013-2023
4.2.6 Boehringer Ingelheim's BI695501 (adalimumab): Revenue Forecast, 2013-2023
4.2.7 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue Forecast, 2013-2023
4.2.8 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast, 2013-2023
4.2.9 Celltrion's CT-P06 (trastuzumab): Revenue Forecast, 2013-2023
4.2.10 Biocon's Bmab200 (trastuzumab): Revenue Forecast, 2013-2023
4.2.11 BIOCAD's BCD-022 (trastuzumab): Revenue Forecast, 2013-2023
4.2.12 Isu Abxis' Clotinab (abciximab): Revenue Forecast, 2013-2023
4.2.13 Reliance Life Sciences' R-TPR-019 (abciximab): Revenue Forecast, 2013-2023
5. LEADING NATIONAL MARKETS FOR BIOSIMILAR MONOCLONAL ANTIBODIES, 2013-2023
5.1 What Were the Leading National Markets for Biosimilar Monoclonal Antibody Development in 2012?
5.2 What Were the Leading National Markets for Sales of Biosimilar Monoclonal Antibodies in 2012?
5.3 Which Markets Will Grow Fastest to 2023?
5.4 Market Shares of the Leading National Markets: All Set to Change, 2013-2023
5.5 The Outlook for Biosimilar MAbs in the US, 2013-2023
5.5.1 When Are the Final FDA Biosimilar Guidelines Expected?
5.5.2 Legal Challenges for Biosimilars in the US
5.5.3 State Regulation of Biosimilar Substitution
5.5.4 The US Biosimilar MAb Market: Revenue Forecast, 2013-2023
5.6 The Outlook for Monoclonal Antibody Biosimilars in the EU, 2013-2023
5.6.1 The EU Led the World in Biosimilar Regulation
5.6.2 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar MAbs
5.6.3 EMA Simplifies Biosimilar Development in the EU
5.6.4 Biosimilar MAbs: EU Launch in 2014?
5.6.5 Germany: Set to Become the Largest National Market for Biosimilar MAbs in the EU
5.6.6 France: Will the Uptake of Biosimilar MAbs Be Restricted?
5.6.7 UK: Drug Uptake Will Be High
5.6.8 Italy: Healthcare Spending Cuts Will Drive Growth
5.6.9 Spain: High Biosimilar MAb Discounts Expected
5.7 The Outlook for Monoclonal Antibody Biosimilars in China, 2013-2023
5.7.1 China to Release Formal Biosimilar Development Guidelines
5.7.2 China: Becoming the World's Leading Market for Biosimilar MAbs
5.8 The Outlook for Monoclonal Antibody Biosimilars in India, 2013-2023
5.8.1 India Releases New Biosimilar Development Guidelines
5.8.2 Indian Biosimilars Submarket Forecast 2013-2023
5.9 The Outlook for Monoclonal Antibody Biosimilars in Japan 2013-2023
5.9.1 Regulatory Processes for Biosimilars in Japan
5.9.2 Regulations for Naming Biosimilars
5.9.3 Biosimilar MAbs Will Be Launched in Japan in 2016
5.9.4 Japanese Biosimilar Submarket Forecast 2013-2023
5.10 South Korea: The World's leading Nation for Biosimilar MAbs
5.10.1 KFDA Introduced Biosimilar Guidelines in 2009
5.10.2 There Has Been Significant Investment in Biosimilars in South Korea
5.10.3 The Outlook for the South Korean Biosimilar MAb Market, 2013-2023
5.11 Brazil: The Third Leading Nation in the 2012 Biosimilar MAb Market, But What Will The Future Hold?
5.11.1 ANVISA's Biosimilar Regulations Are Similar to the EMA's
5.11.2 The Outlook for Monoclonal Antibody Biosimilars in Brazil, 2013-2023
5.12 The Outlook for Monoclonal Antibody Biosimilars in Russia, 2013-2023
5.12.1 No Specific Biosimilar Legislation Exists in Russia 2013
5.12.2 Russian Government Investing in Development of Biosimilars
5.12.3 Russian Biosimilar MAb Revenue Forecast 2013-2023
6. LEADING COMPANIES FOR BIOSIMILAR MABS, 2013
6.1 Prominent Companies in the Biosimilar Monoclonal Antibodies Industry, 2013
6.2 Collaboration in Biosimilar MAb Development
6.3 BioXpress: 16 Compounds in the R&D Pipeline
6.4 Celltrion: One Compound on the Market and Two in Phase III of Development, and Others Wait In The Wings
6.5 Harvest Moon: 6 Compounds Under Development
6.6 Gene Techno Science: 6 Compounds Under Development
6.7 Mabion: Poland's Leading Biosimilar MAb Developer
6.8 India's Biocon: A Quiet Competitor
6.9 Pfizer: Big Pharma Is Entering the Biosimilar MAb Market
6.10 BIOCAD
6.11 Big Pharma and the Biosimilar MAbs Market
7. QUALITATIVE ANALYSIS OF THE BIOSIMILAR MABS MARKET, 2013-2023
7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibody Market, 2013
7.1.1 Worldwide Demand for More Affordable Therapies Underpins the Market
7.1.2 The Complexity of the Molecules Engenders a Myriad of Market Weaknesses
7.2 Opportunities and Threats Facing the Biosimilar Monoclonal Antibody Market, 2013-2023
7.2.1 A Well-Stocked Pipeline in the Face of Approaching Patent Expiries: Opportunities for Market Expansion
7.2.2 Competition and Lack of Confidence: Threats to Market Penetration?
7.2.2.1 Biobetters as a Threat to Biosimilars
7.3 Social, Technological, Economic and Political Factors Influencing the Biosimilar Monoclonal Antibodies Market (STEP Analysis) 2013-2023
7.3.1 Social Factors: Driving or Restraining the Market?
7.3.2 Advances in Technology: Producing Biosimilar MAbs Cheaply and Easily
7.3.3 Economic Pressures are Driving the Demand for Biosimilar MAbs
7.3.4 Political Issues: Stringent Regulations are Hurdles to Market Entry
8. RESEARCH INTERVIEWS
8.1 Interview with Dr Xing Wang, President of Array Bridge
8.1.1 On Challenges Surrounding the Development of Biosimilar MAbs
8.1.2 On the Services Offered by Array Bridge
8.1.3 On the Demand for Biosimilar MAbs
8.1.4 On Factors Determining the Success of Biosimilar MAbs
8.1.5 On Regulatory Approval of Biosimilar MAbs: The US vs. the EU
8.2 Interview With Dr Terence Ryan, SVP, iBio
8.2.1 iBio and its Biosimilar Pipeline, 2013
8.2.2 The iBioLaunch Platform
8.2.3 Differences Between Developing Biosimilar and Biologics
8.2.4 Product Differentiation in the Biosimilar Market
8.2.5 Biosimilars and Immunogenicity
8.2.6 Challenges in Developing Biosimilars for the US Market
9. CONCLUSIONS
9.1 Biosimilar Monoclonal Antibodies: World Market, 2013-2023
9.2 The Future of Promising Pipeline Compounds
9.3 Leading National Markets for Biosimilar Monoclonal Antibodies, 2013-2023
9.4 Leading Companies in the Industry
9.5 Trends in the Industry and Market
9.5.1 Economic Pressures Stimulate Demand for MAbs
9.5.2 Patent Expiries of Several Blockbuster MAbs Are Approaching, Creating Opportunities for Biosimilars
9.5.3 Complexity of the Molecules Make Production Challenging
9.5.4 Doctor and Patient Doubt Regarding Interchangeability Will Restrict Uptake
9.5.5 Do Biobetters Pose a Threat?
LIST OF TABLES
Table 2.1 Classification of Monoclonal Antibodies
Table 2.2 Murine Monoclonal Antibodies on the Market, 2013
Table 2.3 Chimeric Monoclonal Antibodies on the Market, 2013
Table 2.4 Humanised Monoclonal Antibodies on the Market, 2013
Table 2.5 Fully Human Monoclonal Antibodies on the Market, 2013
Table 2.6 Top 10 Prescription Drugs by Revenue ($m), 2012
Table 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Revenue ($m) and Market Share (%), 2012
Table 3.2 Biosimilar MAb World Market: Revenue Forecast ($m), 2012-2023
Table 3.3 The World Market for Biosimilar MAbs: Revenues ($m) and Market Shares (%) by Compound, 2018 and 2023
Table 3.4 Major Originator Biologic Products: EU and US Patent Expiry Dates
Table 3.5 Biosimilar MAbs: Revenue Forecasts ($m) by Molecule, 2012-2023
Table 3.6 Biosimilar Infliximab: Compounds in the Pipeline, 2013
Table 3.7 Biosimilar Infliximab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.8 Biosimilar Rituximab: Compounds in the Pipeline, 2013
Table 3.9 Biosimilar Rituximab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.10 Biosimilar Abciximab: Compounds in the Pipeline, 2013
Table 3.11 Biosimilar Abciximab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.12 Biosimilar Trastuzumab: Compounds in the Pipeline, 2013
Table 3.13 Biosimilar Trastuzumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.14 Biosimilar Adalimumab: Compounds in Development, 2013
Table 3.15 Biosimilar Adalimumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.16 Biosimilar Bevacizumab: Compounds in the Pipeline, 2013
Table 3.17 Biosimilar Bevacizumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.1 Biosimilar MAb Versions on the Market: Revenues ($m) and Market Shares (%), 2012
Table 4.2 Biosimilar Versions on the Market and in the Pipeline: Revenue Forecasts ($m), 2012-2023
Table 4.3 Celltrion's Remsima: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.4 Epirus Biopharmaceuticals' BOW-015: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.5 Dr. Reddy's Reditux: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.6 Boehringer Ingelheim's BI695500: Revenue Forecast, 2012-2023
Table 4.7 Celltrion's CT-P10: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.8 Boehringer Ingelheim's BI695501: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.9 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.10 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.11 Celltrion's CT-P06: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.12 Biocon's Bmab200: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.13 BIOCAD's BCD-022: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.14 Isu Abxis' Clotinab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.15 Reliance Life Sciences' R-TPR-019: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.1 Prominent Companies With 2+ Biosimilar MAbs in Development and Their Country of Origin, 2013
Table 5.2 The Biosimilar MAb Market by Country: Revenues ($m) and Market Shares (%), 2012
Table 5.3 The Biosimilar MAb Market by Country: Grouped Revenue Forecasts ($m), 2012-2023
Table 5.4 The Biosimilar MAb Market: National Market Shares (%), 2013-2023
Table 5.5 The US Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.6 EU5 Biosimilar MAb Markets: Overall Revenue ($m) and Market Share (%) Forecasts by Country, 2012-2023
Table 5.7 The German Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.8 The French Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.9 The UK Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.10 The Italian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.11 The Spanish Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.12 The Chinese Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.13 The Indian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.14 The Japanese Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.15 The South Korean Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.16 The Brazilian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.17 The Russian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 6.1 Companies in the Biosimilar MAb Industry by Number of Compounds in Development, 2013
Table 6.2 Selected Collaborations for Biosimilar MAb Development, 2009-2013
Table 6.3 BioXpress: Compounds in the Pipeline, 2013
Table 6.4 The Tests Carried Out By BioXpress During Biosimilar MAb Development and Their Objectives
Table 6.5 Compounds in Celltion's Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2013
Table 6.6 Gene Techno Science: Revenue and Gross Profit ($m), Year Ended March 2012 and 2013
Table 6.7 Mabion: Compounds in the Pipeline and Their Development Stage, 2013
Table 6.8 Biocon: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.9 Pfizer: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.10 BIOCAD: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.11 Big Pharma's Positions in the Biosimilar MAb Industry, 2013
Table 7.1 Strengths and Weaknesses of the Biosimilar MAb Market, 2013
Table 7.2 Opportunities and Threats Facing the Biosimilar MAb Market, 2013-2023
Table 7.3 Social, Technological, Economic and Political Factors Influencing the Biosimilar MAb Market (STEP Analysis), 2013-2023
Table 2.1 Classification of Monoclonal Antibodies
Table 2.2 Murine Monoclonal Antibodies on the Market, 2013
Table 2.3 Chimeric Monoclonal Antibodies on the Market, 2013
Table 2.4 Humanised Monoclonal Antibodies on the Market, 2013
Table 2.5 Fully Human Monoclonal Antibodies on the Market, 2013
Table 2.6 Top 10 Prescription Drugs by Revenue ($m), 2012
Table 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Revenue ($m) and Market Share (%), 2012
Table 3.2 Biosimilar MAb World Market: Revenue Forecast ($m), 2012-2023
Table 3.3 The World Market for Biosimilar MAbs: Revenues ($m) and Market Shares (%) by Compound, 2018 and 2023
Table 3.4 Major Originator Biologic Products: EU and US Patent Expiry Dates
Table 3.5 Biosimilar MAbs: Revenue Forecasts ($m) by Molecule, 2012-2023
Table 3.6 Biosimilar Infliximab: Compounds in the Pipeline, 2013
Table 3.7 Biosimilar Infliximab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.8 Biosimilar Rituximab: Compounds in the Pipeline, 2013
Table 3.9 Biosimilar Rituximab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.10 Biosimilar Abciximab: Compounds in the Pipeline, 2013
Table 3.11 Biosimilar Abciximab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.12 Biosimilar Trastuzumab: Compounds in the Pipeline, 2013
Table 3.13 Biosimilar Trastuzumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.14 Biosimilar Adalimumab: Compounds in Development, 2013
Table 3.15 Biosimilar Adalimumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.16 Biosimilar Bevacizumab: Compounds in the Pipeline, 2013
Table 3.17 Biosimilar Bevacizumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.1 Biosimilar MAb Versions on the Market: Revenues ($m) and Market Shares (%), 2012
Table 4.2 Biosimilar Versions on the Market and in the Pipeline: Revenue Forecasts ($m), 2012-2023
Table 4.3 Celltrion's Remsima: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.4 Epirus Biopharmaceuticals' BOW-015: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.5 Dr. Reddy's Reditux: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.6 Boehringer Ingelheim's BI695500: Revenue Forecast, 2012-2023
Table 4.7 Celltrion's CT-P10: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.8 Boehringer Ingelheim's BI695501: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.9 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.10 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.11 Celltrion's CT-P06: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.12 Biocon's Bmab200: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.13 BIOCAD's BCD-022: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.14 Isu Abxis' Clotinab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.15 Reliance Life Sciences' R-TPR-019: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.1 Prominent Companies With 2+ Biosimilar MAbs in Development and Their Country of Origin, 2013
Table 5.2 The Biosimilar MAb Market by Country: Revenues ($m) and Market Shares (%), 2012
Table 5.3 The Biosimilar MAb Market by Country: Grouped Revenue Forecasts ($m), 2012-2023
Table 5.4 The Biosimilar MAb Market: National Market Shares (%), 2013-2023
Table 5.5 The US Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.6 EU5 Biosimilar MAb Markets: Overall Revenue ($m) and Market Share (%) Forecasts by Country, 2012-2023
Table 5.7 The German Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.8 The French Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.9 The UK Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.10 The Italian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.11 The Spanish Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.12 The Chinese Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.13 The Indian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.14 The Japanese Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.15 The South Korean Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.16 The Brazilian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.17 The Russian Biosimilar MAb Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 6.1 Companies in the Biosimilar MAb Industry by Number of Compounds in Development, 2013
Table 6.2 Selected Collaborations for Biosimilar MAb Development, 2009-2013
Table 6.3 BioXpress: Compounds in the Pipeline, 2013
Table 6.4 The Tests Carried Out By BioXpress During Biosimilar MAb Development and Their Objectives
Table 6.5 Compounds in Celltion's Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2013
Table 6.6 Gene Techno Science: Revenue and Gross Profit ($m), Year Ended March 2012 and 2013
Table 6.7 Mabion: Compounds in the Pipeline and Their Development Stage, 2013
Table 6.8 Biocon: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.9 Pfizer: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.10 BIOCAD: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.11 Big Pharma's Positions in the Biosimilar MAb Industry, 2013
Table 7.1 Strengths and Weaknesses of the Biosimilar MAb Market, 2013
Table 7.2 Opportunities and Threats Facing the Biosimilar MAb Market, 2013-2023
Table 7.3 Social, Technological, Economic and Political Factors Influencing the Biosimilar MAb Market (STEP Analysis), 2013-2023
LIST OF FIGURES
Figure 2.1 Depiction of an Antibody
Figure 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Market Share (%), 2012
Figure 3.2 The World Market for Biosimilar MAbs: Revenue Forecast ($m), 2012-2023
Figure 3.3 The Biosimilar MAb Market: Market Share (%) by Compound, 2018
Figure 3.4 The Biosimilar MAb Market: Market Share (%) by Compound, 2023
Figure 3.5 Biosimilar Infliximab: Revenue Forecast ($m), 2012-2023
Figure 3.6 Biosimilar Rituximab: Revenue Forecast ($m), 2012-2023
Figure 3.7 Biosimilar Abciximab: Revenue Forecast ($m), 2012-2023
Figure 3.8 Biosimilar Trastuzumab: Revenue Forecast ($m), 2012-2023
Figure 3.9 Biosimilar Adalimumab: Revenue Forecast ($m), 2012-2023
Figure 3.10 Biosimilar Bevacizumab: Revenue Forecast ($m), 2012-2023
Figure 3.11 Biosimilar MAbs: Market Drivers and Restraints, 2013-2023
Figure 4.1 Biosimilar MAb Versions on the Market: Market Share (%), 2012
Figure 4.2 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2018
Figure 4.3 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2023
Figure 4.4 Celltrion's Remsima: Revenue Forecast ($m), 2012-2023
Figure 4.5 Epirus Biopharmaceuticals' BOW-015: Revenue Forecast ($m), 2012-2023
Figure 4.6 Dr. Reddy's Reditux: Revenue Forecast, 2012-2023
Figure 4.7 Boehringer Ingelheim's BI695500: Revenue Forecast, 2012-2023
Figure 4.8 Celltrion's CT-P10: Revenue Forecast ($m), 2012-2023
Figure 4.9 Boehringer Ingelheim's BI695501: Revenue Forecast ($m), 2012-2023
Figure 4.10 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue Forecast ($m), 2012-2023
Figure 4.11 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast ($m), 2012-2023
Figure 4.12 Celltrion's CT-P06: Revenue Forecast, 2012-2023
Figure 4.13 Biocon's Bmab200: Revenue Forecast ($m), 2012-2023
Figure 4.14 BIOCAD's BCD-022: Revenue Forecast ($m), 2012-2023
Figure 4.15 Isu Abxis' Clotinab: Revenue Forecast ($m), 2012-2023
Figure 4.16 Reliance Life Sciences' R-TPR-019: Revenue Forecast ($m), 2012-2023
Figure 5.1 Geographical Distribution (%) of Prominent Compounds Under Development, 2013
Figure 5.2 The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2012
Figure 5.3 The Biosimilar MAb Market: National Submarket Shares (%), 2017
Figure 5.4 The Biosimilar MAb Market: National Submarket Shares (%), 2023
Figure 5.5 FDA Biosimilar Guidelines 2012: Key Points
Figure 5.6 Biosimilar MAbs in the US: Revenue Forecast ($m), 2012-2023
Figure 5.7 The EU5 Biosimilar MAb Market: Grouped Revenue Forecast ($m), 2012-2023
Figure 5.8 The EU5 Biosimilar MAb Market: Revenue Forecasts ($m) by Country, 2012-2023
Figure 5.9 The German Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.10 The French Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.11 The UK Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.12 The Italian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.13 The Spanish Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.14 The Chinese Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.15 The Indian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.16 The Japanese Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.17 The South Korean Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.18 The Brazilian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.19 The Russian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 6.1 Prominent Companies in the Biosimilar MAb Industry: Share (%) of the Pipeline, 2013
Figure 9.1 Prominent Compounds in the Biosimilar MAb Market: Comparison of Revenues ($m), 2013, 2018 and 2023
Figure 9.2 Promising Versions of Biosimilar MAbs: Comparison of Revenues ($m), 2013, 2018 and 2023
Figure 9.3 Leading National Markets: Revenues ($m), 2013, 2018 and 2023
Figure 9.4 Prominent Companies in the Biosimilar MAb Industry: Number of Products in the Pipeline, 2013
COMPANIES LISTED
Abbott Laboratories
AbbVie
AchГ
Actavis
AET BioTech
AgГЄncia Nacional de VigilГўncia SanitГЎria (ANVISA)
Amgen
Aprogen
Array Bridge
AstraZeneca
Bayer
BIO
BIOCAD
Biocon
Biogen Idec
Bionovis
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Cell Therapeutics
Celltrion
Coherus BioSciences
Daiichi Sankyo
Dong-A
Dr. Reddy's Laboratories
Egis Pharmaceuticals
Eli Lilly
Emcure
EMS
Epirus Biopharmaceuticals
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Fresenius
Fujifilm Kyowa Kirin Biologics
Gedeon Richter
Gene Techno Science
Genentech
Genor Biopharma
GlaxoSmithKline
Glycotope
Hanwha Chemical
Harvest Moon
Health Canada
Hospira
Hypermarcas
iBio
Instas Pharmaceuticals
Instituto Vital Brazil
Isu Abxis
Johnson & Johnson
Korean Food and Drug Administration (KFDA)
LG Life Sciences
Lonza
Mabion
Mabxience
Medicines and Healthcare Products Regulatory Agency (MHRA)
MedImmune
Merck & Co.
Merck Serono
Ministry of Health, Labour and Welfare (MHLW)
Mochida Pharmaceutical
Mylan
Natco Pharma
National Institute for Health and Care Excellence (NICE)
Nichi-Iko Pharmaceutical Co.
Nippon Kayaku
Novartis
Oncobiologics
Parexel
Pfizer
Pharma Praxis
PhRMA
Plantform
Probiomed
Quintiles
Reliance Life Sciences
Roche
Samsung
Samsung Bioepis
Sandoz
Sanofi
Schnell
Seattle Genetics
Shanghai CP Guojian
Spectrum Pharmaceuticals
Stada
State Food and Drug Administration (SFDA)
Synthon
Teva Pharmaceutical Industries
UniГЈo QuГmica
Viropro
World Health Organization (WHO)
Wyeth
Zenotech
Figure 2.1 Depiction of an Antibody
Figure 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Market Share (%), 2012
Figure 3.2 The World Market for Biosimilar MAbs: Revenue Forecast ($m), 2012-2023
Figure 3.3 The Biosimilar MAb Market: Market Share (%) by Compound, 2018
Figure 3.4 The Biosimilar MAb Market: Market Share (%) by Compound, 2023
Figure 3.5 Biosimilar Infliximab: Revenue Forecast ($m), 2012-2023
Figure 3.6 Biosimilar Rituximab: Revenue Forecast ($m), 2012-2023
Figure 3.7 Biosimilar Abciximab: Revenue Forecast ($m), 2012-2023
Figure 3.8 Biosimilar Trastuzumab: Revenue Forecast ($m), 2012-2023
Figure 3.9 Biosimilar Adalimumab: Revenue Forecast ($m), 2012-2023
Figure 3.10 Biosimilar Bevacizumab: Revenue Forecast ($m), 2012-2023
Figure 3.11 Biosimilar MAbs: Market Drivers and Restraints, 2013-2023
Figure 4.1 Biosimilar MAb Versions on the Market: Market Share (%), 2012
Figure 4.2 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2018
Figure 4.3 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2023
Figure 4.4 Celltrion's Remsima: Revenue Forecast ($m), 2012-2023
Figure 4.5 Epirus Biopharmaceuticals' BOW-015: Revenue Forecast ($m), 2012-2023
Figure 4.6 Dr. Reddy's Reditux: Revenue Forecast, 2012-2023
Figure 4.7 Boehringer Ingelheim's BI695500: Revenue Forecast, 2012-2023
Figure 4.8 Celltrion's CT-P10: Revenue Forecast ($m), 2012-2023
Figure 4.9 Boehringer Ingelheim's BI695501: Revenue Forecast ($m), 2012-2023
Figure 4.10 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue Forecast ($m), 2012-2023
Figure 4.11 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast ($m), 2012-2023
Figure 4.12 Celltrion's CT-P06: Revenue Forecast, 2012-2023
Figure 4.13 Biocon's Bmab200: Revenue Forecast ($m), 2012-2023
Figure 4.14 BIOCAD's BCD-022: Revenue Forecast ($m), 2012-2023
Figure 4.15 Isu Abxis' Clotinab: Revenue Forecast ($m), 2012-2023
Figure 4.16 Reliance Life Sciences' R-TPR-019: Revenue Forecast ($m), 2012-2023
Figure 5.1 Geographical Distribution (%) of Prominent Compounds Under Development, 2013
Figure 5.2 The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2012
Figure 5.3 The Biosimilar MAb Market: National Submarket Shares (%), 2017
Figure 5.4 The Biosimilar MAb Market: National Submarket Shares (%), 2023
Figure 5.5 FDA Biosimilar Guidelines 2012: Key Points
Figure 5.6 Biosimilar MAbs in the US: Revenue Forecast ($m), 2012-2023
Figure 5.7 The EU5 Biosimilar MAb Market: Grouped Revenue Forecast ($m), 2012-2023
Figure 5.8 The EU5 Biosimilar MAb Market: Revenue Forecasts ($m) by Country, 2012-2023
Figure 5.9 The German Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.10 The French Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.11 The UK Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.12 The Italian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.13 The Spanish Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.14 The Chinese Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.15 The Indian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.16 The Japanese Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.17 The South Korean Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.18 The Brazilian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 5.19 The Russian Biosimilar MAb Market: Revenue Forecast ($m), 2012-2023
Figure 6.1 Prominent Companies in the Biosimilar MAb Industry: Share (%) of the Pipeline, 2013
Figure 9.1 Prominent Compounds in the Biosimilar MAb Market: Comparison of Revenues ($m), 2013, 2018 and 2023
Figure 9.2 Promising Versions of Biosimilar MAbs: Comparison of Revenues ($m), 2013, 2018 and 2023
Figure 9.3 Leading National Markets: Revenues ($m), 2013, 2018 and 2023
Figure 9.4 Prominent Companies in the Biosimilar MAb Industry: Number of Products in the Pipeline, 2013
COMPANIES LISTED
Abbott Laboratories
AbbVie
AchГ
Actavis
AET BioTech
AgГЄncia Nacional de VigilГўncia SanitГЎria (ANVISA)
Amgen
Aprogen
Array Bridge
AstraZeneca
Bayer
BIO
BIOCAD
Biocon
Biogen Idec
Bionovis
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Cell Therapeutics
Celltrion
Coherus BioSciences
Daiichi Sankyo
Dong-A
Dr. Reddy's Laboratories
Egis Pharmaceuticals
Eli Lilly
Emcure
EMS
Epirus Biopharmaceuticals
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Fresenius
Fujifilm Kyowa Kirin Biologics
Gedeon Richter
Gene Techno Science
Genentech
Genor Biopharma
GlaxoSmithKline
Glycotope
Hanwha Chemical
Harvest Moon
Health Canada
Hospira
Hypermarcas
iBio
Instas Pharmaceuticals
Instituto Vital Brazil
Isu Abxis
Johnson & Johnson
Korean Food and Drug Administration (KFDA)
LG Life Sciences
Lonza
Mabion
Mabxience
Medicines and Healthcare Products Regulatory Agency (MHRA)
MedImmune
Merck & Co.
Merck Serono
Ministry of Health, Labour and Welfare (MHLW)
Mochida Pharmaceutical
Mylan
Natco Pharma
National Institute for Health and Care Excellence (NICE)
Nichi-Iko Pharmaceutical Co.
Nippon Kayaku
Novartis
Oncobiologics
Parexel
Pfizer
Pharma Praxis
PhRMA
Plantform
Probiomed
Quintiles
Reliance Life Sciences
Roche
Samsung
Samsung Bioepis
Sandoz
Sanofi
Schnell
Seattle Genetics
Shanghai CP Guojian
Spectrum Pharmaceuticals
Stada
State Food and Drug Administration (SFDA)
Synthon
Teva Pharmaceutical Industries
UniГЈo QuГmica
Viropro
World Health Organization (WHO)
Wyeth
Zenotech
